M1033 Pharmacotherapy Initiation HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS Level II M1033: Pharmacotherapy Initiation for Opioid Use Disorder

HCPCS Level II code M1033 designates initiation of pharmacotherapy for opioid use disorder (OUD) that begins after June 30 of the performance period. As a service-level code, it captures the clinical milestone of starting medication-assisted treatment during the latter half of a measurement interval, which is relevant for quality reporting, population health management, and program tracking across payers nationally. The code matters because timely initiation of pharmacotherapy is associated with improved retention in treatment and reduced overdose risk, making accurate coding important for care coordination and performance measurement.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, the clinical and service context for its use, and the kinds of benchmarks and policy updates typically associated with OUD pharmacotherapy codes. The publication outlines how M1033 is used in reporting frameworks, common service settings where initiation occurs, and the implications for payer performance measures and program monitoring.

The content provides practical reference material for billing, compliance, and clinical operations teams seeking to align documentation and reporting with national payer expectations. Data not available in the input.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1033HCPCS Level IIopioid use disorderpharmacotherapy initiationquality reportingmedication-assisted treatmentbehavioral healthoutpatient treatment

Billing Code Overview

HCPCS Level II code M1033 indicates pharmacotherapy for opioid use disorder (OUD) initiated after June 30 of the performance period. The code describes the initiation of medication-based treatment as a clinical intervention for OUD.

Service type: Pharmacotherapy initiation for opioid use disorder
Typical site of service: Outpatient clinics or community-based treatment settings where medication for OUD is started

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 28–45 year-old adult with opioid use disorder (OUD) who presents for initiation of pharmacotherapy after June 30 of the performance period. The patient has had an initial assessment by a clinician credentialed to treat substance use disorders, including medical history, substance use history, mental health screening, and medication risk review. Clinical workflow includes verification of OUD diagnosis, informed consent, baseline vitals and urine drug screen, evaluation for co-occurring conditions, discussion of medication options (buprenorphine, methadone where available, or extended-release naltrexone), and initiation of the chosen pharmacotherapy with education on dosing, adverse effects, take-home instructions, and follow-up scheduling. Medication ordering, documentation of treatment start date, and coordination with pharmacy, behavioral health counseling, and care management are completed. Typical sites of service include outpatient addiction treatment programs, office-based opioid treatment (OBOT) clinics, federally qualified health centers, and hospital outpatient departments. Common patient scenario: new OBOT patient previously not engaged in treatment presenting to an addiction medicine clinic requesting initiation of buprenorphine after a referral from the emergency department for recent non-fatal overdose; clinician confirms OUD, performs induction per protocol, documents initiation date after June 30 of the performance period, arranges close follow-up and counseling referral.

Coding Specifications

Modifier	Description	When to Use
`22`

HCPCS Level II M1042: Oswestry Disability Index Preop and 1-Year Postop

HCPCS-M1055-ASPIRIN-ANTIPLATELET-THERAPY-USED

HCPCS Level II M1055: Aspirin or Other Antiplatelet Therapy Used

HCPCS-M1032-ADULT-PHARMACOTHERAPY-OUD-MANAGEMENT

HCPCS M1032: Adult Pharmacotherapy for OUD

HCPCS-LEVEL-II-M1022-HOSPICE-ENROLLED-PATIENTS

HCPCS Level II M1022: Patients Enrolled in Hospice During Performance Period

HCPCS-M1070-PATIENT-NOT-SCREENED-FALL-RISK

HCPCS Level II M1070: Patient Not Screened for Future Fall Risk

HCPCS-M1015-DISCHARGE-EPISODE-OF-CARE

HCPCS Level II M1015: Discharge/Discontinuation of Episode of Care

HCPCS-M1003-TB-SCREENING-BEFORE-BIOLOGIC-INITIATION

HCPCS Level II M1003: Tb Screening Prior to First-Time Biologic Therapy

HCPCS-M1067-HOSPICE-SERVICES-MEASUREMENT-PERIOD

HCPCS Level II M1067: Hospice Services During Measurement Period

HCPCS-M1048-OSWESTRY-DISABILITY-INDEX-PRE-POST-OP-ASSESSMENT

HCPCS M1048: Oswestry Disability Index Preoperative and 3-Month Postoperative Assessment

HCPCS-M1054-URGENT-CARE-ONLY-VISITS

HCPCS M1054: Urgent Care–Only Visits

Showing 1–10 of 67

Taxonomy Code	Specialty	Notes
2084P0400X	Addiction Medicine	Physicians who evaluate and initiate medication for opioid use disorder.
208U00000X	Family Medicine	Primary care clinicians who provide office-based opioid treatment and pharmacotherapy initiation.
208D00000X	Internal Medicine	Internists who manage OUD pharmacotherapy in outpatient settings.
363L00000X	Nurse Practitioner	NPs who frequently perform medication induction and follow-up in clinics.
367A00000X	Physician Assistant	PAs who support initiation and management of OUD pharmacotherapies.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Primary diagnosis indicating opioid use disorder for which pharmacotherapy initiation is indicated.
`F11.21`	Opioid dependence, in remission	Relevant for documentation if initiating maintenance pharmacotherapy after recent remission or relapse.
`F11.10`	Opioid abuse, uncomplicated	May be used where opioid use disorder is characterized as abuse without dependence in some coding contexts.
`F11.23`	Opioid dependence with withdrawal	Important when induction timing must consider withdrawal symptoms for buprenorphine initiation.
`F11.24`	Opioid dependence with opioid-induced mood disorder	Relevant when co-occurring mood disorder affects treatment planning during initiation.
`Z79.891`	Long term (current) use of opiate analgesic	Used to document chronic opioid exposure which may impact induction strategy.
`R78.89`	Other specified abnormal findings of blood chemistry (e.g., positive urine drug screen)	Supports baseline testing and monitoring during initiation.
`Z71.53`	Encounter for screening and surveillance of substance use and counseling	Used when initiation visit includes structured counseling and screening services.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99204`	Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	Used for detailed initial evaluation preceding pharmacotherapy initiation when moderate complexity documentation is present.
`99205`	Office or other outpatient visit for the evaluation and management of a new patient, high complexity	Used when the initial assessment is high complexity prior to medication induction.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Behavioral counseling code commonly provided during substance use treatment visits; may be used adjunctively.
`99407`	Smoking and tobacco use cessation counseling visit, intensive, greater than 10 minutes	Used when intensive counseling is delivered at the same visit as pharmacotherapy initiation.
`90832`	Psychotherapy, 30 minutes with patient	Behavioral health counseling performed alongside medication initiation; commonly billed when integrated behavioral services are provided.
`81025`	Urinalysis, non-automated, with microscopy	Point-of-care urine drug screen or urinalysis performed at initiation visit to document baseline substance use.

OpenPayer